EPRX: Once-yearly therapy for EoE targets compliance and durability, with pivotal data due in December
EoE is a rapidly growing market with significant unmet needs, and a once-yearly, physician-administered therapy is positioned to address compliance and durability challenges. Interim Phase IIb data in December will provide detailed efficacy and safety insights, supporting expansion into related ind…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.